Company intelligence / Profile preview
Chengdu Huasun Biotechnology
Chengdu, Sichuan, Chinahuasungrp.com ↗
- Ownership
- Private
- Employees
- ~918
- Development stage
- Other
01
Overview
Developed Iodine[131I] metuximab ("Licartin")—a pioneering Chinese Class I oncology drug targeting CD147 approved for hepatocellular carcinoma. Also involved in development and clinical evaluation of freeze-dried recombinant human epidermal growth factor eye drops.
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Therapeutic radiopharmaceuticalsRadiolabeled antibodyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chengdu Huasun Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Huasun Biotechnology.